FDA – Breyanzi: BLA Approval of New Indication (Catapult’s regulatory round-up – June 2024)
FDA approved lisocabtagene maraleucel for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor. Please find further information here.
Published on the 3rd of July in Catapult’s regulatory round-up for June 2024.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (5 novembre 2024). FDA – Breyanzi: BLA Approval of New Indication (Catapult’s regulatory round-up – June 2024). ELSIBI. Consulté le 26 avril 2025 à l’adresse https://doi.org/10.58079/12mj8